نتایج جستجو برای: pharmacokinetic study

تعداد نتایج: 3982380  

2016
Tomoko Hasunuma Masahiro Tohkin Nahoko Kaniwa In‐Jin Jang Cui Yimin Masaru Kaneko Yoshiro Saito Masahiro Takeuchi Hiroshi Watanabe Yasushi Yamazoe Yoshiaki Uyama Shinichi Kawai

AIM To examine whether strict control of clinical trial conditions could reduce apparent differences of pharmacokinetic (PK) parameters among ethnic groups. METHODS Open-label, single dose PK studies of moxifloxacin, simvastatin and meloxicam were conducted in healthy male subjects from three East Asian populations (Japanese, Chinese and Koreans) and one Caucasian population as a control. The...

2013
Joerg J Moehrle Stephan Duparc Christoph Siethoff Paul L M Giersbergen J Carl Craft Sarah Arbe-Barnes Susan A Charman Maria Gutierrez Sergio Wittlin Jonathan L Vennerstrom

AIMS To assess the safety and pharmacokinetics of a new synthetic ozonide antimalarial, OZ439, in a first-in-man, double-blind study in healthy volunteers. METHODS OZ439 was administered as single oral daily doses of a capsule formulation (50-1200 mg) or an oral dispersion (400-1600 mg, fed and fasted states) and for up to 3 days as an oral dispersion (200-800 mg day(-1)). Plasma concentratio...

Journal: :The Journal of pharmacology and experimental therapeutics 2011
Elodie L Plan Guangli Ma Mats Någård Jörgen Jensen Mats O Karlsson

Transient lower esophageal sphincter relaxation (TLESR) is the major mechanism for gastroesophageal reflux. Characterizations of candidate compounds for reduction of TLESRs are traditionally done through summary exposure and response measures and would benefit from model-based analyses of exposure-TLESR events relationships. Pharmacokinetic (PK)-pharmacodynamic (PD) modeling approaches treating...

Journal: :Antimicrobial agents and chemotherapy 2007
Cornelia B Landersdorfer Carl M J Kirkpatrick Martina Kinzig-Schippers Jürgen B Bulitta Ulrike Holzgrabe George L Drusano Fritz Sörgel

Flucloxacillin is often used for the treatment of serious infections due to sensitive staphylococci. The pharmacokinetic (PK)-pharmacodynamic (PD) breakpoint of flucloxacillin has not been determined by the use of population PK. Targets based on the duration of non-protein-bound concentrations above the MIC (fT(>MIC)) best correlate with clinical cure rates for beta-lactams. We compared the bre...

2017

Elvitegravir is an emerging integrase inhibitor. When elvitegravir is taken with a low dose of the drug ritonavir (Norvir), the concentration of elvitegravir in the blood rises and remains elevated for about a day. The manufacturer of elvitegravir, Gilead Sciences, is also developing another pharmacokinetic (PK) booster called cobicistat, which will be co-formulated with elvitegravir in the fut...

2014
Seol Ju Moon Jongtae Lee Hyungmi An Dong-Seok Yim Jae-Yong Chung Kyung-Sang Yu Joo-Youn Cho Kyoung Soo Lim

BACKGROUND AND OBJECTIVE Moxifloxacin 400 mg is a widely used positive control in thorough QT (TQT) studies, but its QT-prolonging effects in Korean subjects have not been studied. The present study was conducted to collect pilot data in Korean subjects after moxifloxacin administration to evaluate the adequacy of moxifloxacin as a positive control. METHODS Thirty-eight, healthy, Korean, male...

Journal: :Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2008
Valérie Morin Jérôme R E Del Castillo Simon Authier Norma Ybarra Colombe Otis Dominique Gauvin Jolanta Gutkowska Eric Troncy

PURPOSE Because oxytocin (OT) is potentially useful in cardiovascular therapy but has hormonal roles on the cardiovascular and renal systems, we characterized its pharmacokinetic (PK) properties as a function of dose. METHODS A single intravenous bolus of OT was given at doses of 200, 300, 500, 1000, 3000, 5000 and 10000 ng/kg to anesthetized male rats (n >= 4 per dose). Blood samples (6) wer...

2018
Linda G Franken Brenda C M de Winter Anniek D Masman Monique van Dijk Frans P M Baar Dick Tibboel Birgit C P Koch Teun van Gelder Ron A A Mathot

AIMS Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired level of sedation. A previous pharmacokinetic (PK) study showed that variability between patients could be partly explained by renal function and inflammatory status. The goal of this study was to combine this PK information with pharmacodynamic (PD) data, to evaluate the variability in response ...

Journal: :Bioorganic & medicinal chemistry letters 2006
Lawrence A Reiter Kevin D Freeman-Cook Christopher S Jones Gary J Martinelli Amy S Antipas Martin A Berliner Kaushik Datta James T Downs James D Eskra Michael D Forman Elaine M Greer Roberto Guzman Joel R Hardink Fouad Janat Nandell F Keene Ellen R Laird Jennifer L Liras Lori L Lopresti-Morrow Peter G Mitchell Jayvardhan Pandit Donald Robertson Diana Sperger Marcie L Vaughn-Bowser Darra M Waller Sue A Yocum

Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and >100-fold selectivity against other MMPs have been identified. Despite high molecular weights, clogPs, and polar surface areas, the compounds are generally well absorbed and have excellent pharmacokinetic (PK) properties when dosed as sodium salts. In a rat fibrosis model, a compo...

Journal: :Paediatric anaesthesia 2010
Isabelle Constant Agnes Rigouzzo

For several years, total intravenous anesthesia (TIVA) has demonstrated many advantages that allow consideration of propofol anesthesia as an interesting alternative in pediatric anesthesia. TIVA in children requires calculation and validation of pharmacokinetic (PK) models specifically adapted to the pediatric population. Several PK models based on a 3-compartment approach have been proposed i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید